This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Quantum Genomics Corp.
Drug Names(s): QGC 001, QGC-001, RB150, QGC101 (CHF), QGC 101 (CHF), QGC-101 (CHF)
QGC001 is a dimer of EC33 ((3S)-3-amino-4-sulfanyl-butane-1-sulfonic acid). This chemical modification allows the pro-drug to cross the BBB when administered systemically. When QGC001 enters the brain, it is immediately cleaved by brain reductases, generating two active molecules of EC33.
EC33 inhibits aminopeptidase A (APA), which is responsible for the conversion of brain angiotensin II to angiotensin III. The latter in turn regulates arterial tone. Preclinical studies suggest targeting brain APA attenuates sympathetic hyperactivity and cardiac dysfunction in rats post-myocardial infarction.
Additional information available to subscribers only: